Clinical Trial Update: ULTRATRACE Iobenguane I 131 in Patients With Malignant Pheochromocytoma, Paraganglioma, or Metastatic Carcinoid [Phase 1]

View source ↗

Summary

Phase 1 clinical trial of Ultratrace iobenguane I-131 in patients with malignant pheochromocytoma, paraganglioma, or metastatic carcinoid has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carcinoid Tumor
• Paraganglioma
• Pheochromocytoma

Drugs mentioned

• Ultratrace Iobenguane I-131 (iobenguane I-131)

Snippet

Sponsor: Molecular Insight Pharmaceuticals, Inc. | Conditions: Pheochromocytoma, Paraganglioma | Phase 1 | Status: COMPLETED